Meiragtx Holdings share price logo

Meiragtx Holdings

NASDAQ: MGTX

Small Cap

$12.88

+0.09

(+0.70%)

as on

Meiragtx Holdings Stock Performance

as on September 15, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $12.76
    $13.22
    downward going graph

    0.93%

    Downside

    2.64%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.62
    $15.35
    downward going graph

    48.60%

    Downside

    19.18%

    Upside

    downward going graph

Meiragtx Holdings share price movements today

Previous Close
$12.79
Open
$12.88
Volume
540.4K
Market Cap
$1.2B
Day's Low - High
$12.76 - $13.22
52 Week Low - High
$6.62 - $15.35

Meiragtx Holdings Historical Returns

1 Month Return
-4.73 %
3 Month Return
+ 32.1 %
1 Year Return
+ 75.72 %
3 Year Return
+ 126.76 %
5 Year Return
+ 0.23 %

Meiragtx Holdings Stock Fundamentals & Key Indicators

Check Meiragtx Holdings market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

0.76

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

16.83

Industry PE ratio

-6.33

PEG Ratio

0.08071760573345069

EBITDA

259.9M

Revenue (TTM)

397.5M

Profit Margin

97.19%

Return On Equity TTM

284.38%

Meiragtx Holdings Stock Valuation

Track how Meiragtx Holdings P/E has moved over time to understand its valuation trends.

Meiragtx Holdings in the last 5 years

  • Overview

  • Trends

Lowest (-13.17x)

December 31, 2021

Industry (-6.33x)

December 31, 2025

Today (-5.60x)

December 31, 2025

Highest (-2.27x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -5.60x

Meiragtx Holdings vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Meiragtx Holdings with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$1.2B0.23%16.8397.19%NA
BUY$44.6B614.61%NA0.00%NA
BUY$130.6B175.08%29.7686.04%NA
BUY$57.5B-66.24%-18.04-12.57%NA
BUY$80.5B21.74%18.9584.86%47.339999999999996%

Stock Returns calculator for Meiragtx Holdings Stock including INR - Dollar returns

The Meiragtx Holdings stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Meiragtx Holdings investment value today

Current value as on today

₹1,90,508

Returns

₹90,508

(+90.51%)

Returns from Meiragtx Holdings Stock

₹75,716 (+75.72%)

Dollar Impact

₹14,792 (+14.79%)

Analyst Recommendation on Meiragtx Holdings Stock

Based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Meiragtx Holdings. Average target price of $29.43

Meiragtx Holdings Share Price Target

Get share price movements and forecasts by analysts on Meiragtx Holdings.

What analysts predicted

56.24%UPSIDE

Target Price

$29.43

Current Price

$12.88

Analyzed by

6 Analysts

Target

$29.43

Meiragtx Holdings target price $29.43, a slight upside of 56.24% compared to current price of $12.88. According to 6 analysts rating.

Indian Investors' Interest in Meiragtx Holdings Stock

Search interest for Meiragtx Holdings Stock has increased by 158% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:158% versus previous 30 day period

Meiragtx Holdings Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
0
0
10
21
1
3
0
75
0
321
Gross Profit
-2
0
-1
9
0
1
0
74
-2
314
Operating Income
-46
-45
-40
-31
-41
-44
-46
26
-40
244
EBITDA
-13
-42
-32
-33
-33
-32
-44
21
-40
323
Interest Expense
3
3
3
3
3
3
3
3
2
3
Depreciation
3
3
3
2
3
3
3
3
3
-
Income Before Tax
-20
-48
-39
-39
-39
-38
-50
15
-46
163
Income Tax Expense
-
-
-
-
-
-
-
-
-
2
Net Income
-20
-48
-39
-39
-39
-38
-50
15
-46
160
Net Profit Margin
-369.87%
100.00%
-9.85%
44.81%
28.45%
27.50%
23.66%
99.37%
-994.20%
97.77%

Meiragtx Holdings Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
13
15
37
15
14
33
81
Gross Profit
0
-2
13
15
37
15
14
9
76
Operating Income
-31
-78
-58
-62
-72
-116
-137
-164
-105
EBITDA
-31
-78
-52
-53
-71
-116
-57
-121
-89
Interest Expense
0
0
0
0
0
4
13
13
12
Depreciation
0
2
2
4
7
8
13
12
12
Income Before Tax
-31
-83
-54
-57
-79
-129
-84
-147
-114
Income Tax Expense
-
0
-
-
-
-
-
-
-
Net Income
-31
-82
-54
-57
-79
-129
-84
-147
-114
Net Profit Margin
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
28.51%
94.05%

Meiragtx Holdings Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-20
-48
-39
-39
-39
-38
-50
-192
-46
46
Operating Cash Flow
-36
-19
-25
-23
-36
-43
-12
46
17
-38
Investing Cash Flow
27
-1
-1
-1
-1
0
0
-1
-2
-23
Financing Cash Flow
-1
1
49
4
1
5
0
5
-10
133
Change in Cash
-10
-19
24
-19
-37
-34
-17
51
5
71

Meiragtx Holdings Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-31
-82
-54
-57
-79
-129
-84
-147
-114
Operating Cash Flow
-18
-58
20
-63
-10
-73
-105
-104
-46
Investing Cash Flow
-10
-11
-9
-37
-61
-44
34
23
-4
Financing Cash Flow
19
130
148
82
1
95
84
54
12
Change in Cash
-9
59
159
-17
-71
-22
15
-24
-37

Mutual Funds that own Meiragtx Holdings Stock

Check out the Mutual Funds with significant holdings in Meiragtx Holdings.

Funds
Holdings
Shares Held
Fidelity Salem Street Trust
0.50545%
485450
VANGUARD SCOTTSDALE FUNDS
0.280571%
269469
TIAA-CREF Funds
0.26117%
250836
VANGUARD WORLD FUND
0.13695%
131531
SCHWAB CAPITAL TRUST
0.104273%
100147

Global Institutional Holdings in Meiragtx Holdings

Funds
Holdings
Joseph Edelman
11.23%
iShares
3.18%
Michael Rockefeller
1.56%
Janus Henderson
0.79%
Vanguard
0.6%

Meiragtx Holdings News & Key Events

  • img

    Today's Timeline - 10 November

    Mon, 05:30 PM

    -

    MeiraGTx collaborates with Eli Lilly to develop AAV-AIPL1 for LCA4, receiving $75 million upfront and potential milestone payments exceeding $400 million.

Insights on Meiragtx Holdings

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 293.0K → 321.43M (in $), with an average increase of 99.9% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MGTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, MGTX stock has moved up by 32.1%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -46.31M → 160.72M (in $), with an average increase of 128.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 514.3% return, outperforming this stock by 438.6%

About Meiragtx Holdings

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
OrganisationMeiragtx Holdings
Headquarters655 Third Avenue, New York, NY, United States, 10017
IndustryBiotechnology
CEODr. Alexandria Forbes Ph.D.
E-voting on sharesClick here to vote

Key Management of Meiragtx Holdings

Name

Title

Dr. Tassos Georgiadis Ph.D.

Senior Vice President of Discovery & Preclinical Development

Mr. Richard Brian Giroux B.A.

COO & CFO

Dr. Stuart Naylor Ph.D.

Chief Scientific Officer of Ophthalmology

Dr. Michel Michaelides F.A.C.S., M.D., MBBS

Head of Clinical Ophthalmology

Mr. Tim Randall

Senior Vice President of Risk & Internal Controls

Dr. David Rubinstein Ph.D.

Senior Vice President of Business Development

Dr. Alexandria Forbes Ph.D.

CEO, President & Director

Dr. Robert K. Zeldin M.D.

Chief Medical Officer

Mr. Robert J. Wollin J.D.

General Counsel & Secretary

Ms. Christine Elise Sheehy

Senior Vice President of Global Integration

FAQs

What is Meiragtx Holdings share price today?

Meiragtx Holdings share price today is $12.88 as on at the close of the market. Meiragtx Holdings share today touched a day high of $13.22 and a low of $12.76.

What is the 52 week high and 52 week low for Meiragtx Holdings share?

Meiragtx Holdings share touched a 52 week high of $15.35 on and a 52 week low of $6.62 on . Meiragtx Holdings stock price today i.e. is closed at $12.88,which is 16.09% down from its 52 week high and 94.56% up from its 52 week low.

What is Meiragtx Holdings's market capitalisation today?

Meiragtx Holdings market capitalisation is $0.00T as on .

How to invest in Meiragtx Holdings Stock (MGTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Meiragtx Holdings on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Meiragtx Holdings Shares that will get you 0.1165 shares as per Meiragtx Holdings share price of $12.88 per share as on September 15, 2026 at 8:46 am IST.

What is the minimum amount required to buy Meiragtx Holdings Stock (MGTX) from India?

Indian investors can start investing in Meiragtx Holdings (MGTX) shares with as little as ₹95.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.40 in Meiragtx Holdings stock (as per the Rupee-Dollar exchange rate as on ). Based on Meiragtx Holdings share’s latest price of $12.88 as on September 15, 2026 at 8:46 am IST, you will get 0.7764 shares of Meiragtx Holdings. Learn more about fractional shares .

What are the returns that Meiragtx Holdings has given to Indian investors in the last 5 years?

Meiragtx Holdings stock has given 0.23% share price returns and 29.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?